N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide | 1396771-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
• 英文别名: N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-yl-6-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazolo[3,4-b]pyridine-4-carboxamide
• CAS: 1396771-79-1
• 化学式: C₂₇H₃₈N₆O₂
• 分子量: 478.638
• InChiKey: XCTNAAHSFDICAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 在 钯 氢气 、 crude material 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give the desired compound (71% yield)的产率得到N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
  参考文献：
  名称：

  Substituted 6,5-Fused Bicyclic Heteroaryl Compounds

  摘要：

  本发明涉及取代的6,5-融合的杂环芳基化合物。本发明还涉及含有这些化合物的制药组合物，并通过将这些化合物和制药组合物用于需要治疗癌症的受试者来治疗癌症的方法。

  公开号：

  US20150266854A1

文献信息

• Substituted 6,5-fused bicyclic heteroaryl compounds
  申请人：Epizyme, Inc.

  公开号：US08962620B2

  公开（公告）日：2015-02-24

  The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的6,5-融合的杂环芳基化合物。本发明还涉及包含这些化合物的制药组合物以及通过向需要的受试者给予这些化合物和制药组合物来治疗癌症的方法。
• SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20130317026A1

  公开（公告）日：2013-11-28

  The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的6,5-融合双环杂芳基化合物。本发明还涉及包含这些化合物的制药组合物以及通过将这些化合物和制药组合物用于需要治疗的受试者来治疗癌症的方法。
• [EN] SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES SUBSTITUÉS CONDENSÉS EN 6,5
  申请人：EPIZYME INC

  公开号：WO2012118812A3

  公开（公告）日：2012-11-08
• INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
  申请人：Epizyme, Inc.

  公开号：EP2825161B1

  公开（公告）日：2019-01-02
• Inhibitors of Human EZH2, and Methods of Use Thereof
  申请人：Kuntz Kevin W.

  公开号：US20130040906A1

  公开（公告）日：2013-02-14

  The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.